Signed in as:
filler@godaddy.com
News and Current Events
iMetabolic Biopharma Found & CEO Featured on the Cover of Top Doctor Magazine
November 1, 2022
iMetabolic Biopharma Corporation (iMBP: Tempe, AZ) proudly announces that its Founder and CEO, Dr. Urban A. Kiernan, was featured on the cover of the latest issue of Top Doctor Magazine. "I am proud to share a portion of my personal story and how I utilize Brazilian Jiu Jitsu as a centering piece to help maintain balance in my life” stated Dr. Kiernan. He added, “I hope that the information shared inspires others to find balance so they take control of their own lives. Life is filled with challenges and it is our individual responsibility to find ways for self-empowerment.”
For the full issue and the artilcle, please follow this link below.
iMetabolic Biopharma Teams With Amazon Web Services Diagnostic Development Initiative
February 15, 2022
iMetabolic Biopharma Corporation (iMBP : Tempe, AZ) announces it has teamed with Amazon Web Services (AWS) to aid in the development of its proprietary iPlatform™ technology. Selected through AWS's Diagnostic Development Initiative, iMBP and AWS are cooperatively working together in developing collective solutions to address COVID-19 and other infectious diseases.
In a statement from Dr. Urban A. Kiernan, the company founder and CEO, "We at iMetabolic Biopharma are incredibly excited to be working with AWS in establishing viable solutions to attack COVID-19. Their support is vital for iMBP's expansion into infectious disease, and we look forward to working with them in solving the challenges that lay before us."
Follow the link below to the Global News Wire press release.
iMetabolic Biopharma Announces the Expansion of Its Strategic Partnership with Ligand
December 17, 2020
iMetabolic Biopharma Corporation (iMBP: Tempe, AZ) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018. In a statement by Bill Harriman, Ph. D., Senior Vice President of Antibody Discovery at Ligand Pharmaceuticals, “The iMetabolic pipeline molecules can be thought of, in essence, as gene therapy implemented purely at the protein level, and represent a strategy that we would be excited to see emerge as a clinically-viable modality.”
Follow the link below to Business Wire press release.
Dr. Stephen Munk Joins the iMetabolic Biopharma Leadership Team
August 14th, 2019
It is our great pleasure to announce that Dr. Stephen Munk has joined the iMetabolic Biopharma Corporation (iMBP) leadership team. In addition to his current role as Deputy Director of the Biodesign Institute at Arizona State University, Dr. Munk has taken on the roles of iMBP Board Director and Interim Chief Operating Officer (COO). With over 25 years of life science, pharmaceutical and executive management experience (including 20 years as the CEO of Ash Stevens Inc.), he brings a wealth of knowledge and experience that iMBP is fortunate to gain as a startup company.
Obesity is driving a health crisis worldwide. Munk said that he is truly excited to be a part of a team dedicated to developing novel approaches to manage this growing crisis. iMetabolic brings a unique perspective to treat this unmet medical challenge.
In a statement from Dr. Urban Kiernan, the company CEO and Chairman, “We are excited that Dr. Munk recognizes the value in the work being undertaken at iMBP and is willing to commit time and effort towards the program. We look forward to his contributions in helping mature iMBP and its products so that we can ultimately benefit as many people as possible.”
Dr. Munk holds a Ph.D. in organic chemistry from the University of California Berkeley and was an American Cancer Society postdoctoral fellow at Purdue using the tools of molecular biology to study drug:DNA interactions. His work has resulted in a number of publications, patents and a book. He was an adjunct professor at Wayne State University and also serves on a number of boards and steering committees, including AZBio and the Arizona Opera.
iMBP and FCS Foundation Join Forces to Create FCS Awareness
February 28th, 2019
In participation of Rare Disease Day, iMetabolic Biopharma Corporation (iMBP) is pleased to announce that they have partnered with the FCS Foundation to create a strategic awareness campaign focused on Familial Chylomicronemia Syndrome (FCS). FCS is a devastating rare disease that prevents sufferers from normally metabolizing dietary fats. Without an approved therapeutic option, iMBP stands hand in hand on the front line with sufferers of this disease to find a solution. However, it all begins with awareness.
Download the full announcement at
https://imbiopharma.com/resources
For more information on the FCS Foundation, please visit https://www.livingwithfcs.org/.
Ligand Pharmaceuticals Announces Partnership with iMBP Corporation
November 21, 2018
Ligand Pharmaceuticals (San Diego, CA; NASDAQ: LGND) announced that it has entered into a partnership agreement with iMetabolic Biopharma Corporation (iMBP), an early stage startup company based in Tempe, AZ developing novel precision medicine therapeutics for the treatment of obesity related diseases. Specific financial information of the agreement were not disclosed, but did include Ligand taking an equity position within the startup company.
In a statement from iMBP Founder & CEO Dr. Urban A. Kiernan, "We are fortunate to have identified a partner in Ligand Pharmaceuticals at such an early stage of our evolution. This is a very exciting time for our company, team and shareholders."
Follow the link below to Business Wire press release.